US2010056761A1PendingUtilityA1
Antibodies against erbb3 and uses thereof
Assignee: MERRIMACK PHARMACEUTICALS INCPriority: Feb 16, 2007Filed: Apr 17, 2009Published: Mar 4, 2010
Est. expiryFeb 16, 2027(~0.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 13/08A61P 13/12A61P 17/00A61P 11/00A61P 1/00A61P 15/00C07K 2317/92C07K 16/2863C07K 16/32C07K 2317/73C07K 2317/21A61K 31/517A61K 39/39558A61K 2039/505A61K 9/0019C07K 2317/55C07K 2317/34A61K 39/3955A61K 31/337C07K 2317/76C07K 2317/565C07K 16/28A61K 39/395A61K 33/243
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.
Claims
exact text as granted — not AI-modified1 . An isolated monoclonal antibody or antigen binding portion thereof that binds to ErbB3 and inhibits EGF-like ligand mediated phosphorylation of ErbB3.
2 - 58 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.